Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

被引：0

作者：

Samoilova, Iuliia G. ^{[1
]}

Vaizova, Olga E. ^{[1
]}

Stankova, Anastasia E. ^{[1
]}

Matveeva, Mariia, V ^{[1
]}

Podchinenova, Daria, V ^{[1
,4
]}

Kudlay, Dmitry A. ^{[2
,3
]}

Borozinets, Anastasiia A. ^{[2
]}

Filippova, Tatyana A. ^{[1
]}

Grishkevich, Ivan R. ^{[1
]}

Partala, Anastasia, V ^{[1
]}

Gerasimova, Diana A. ^{[1
]}

机构：

[1] Siberia State Med Univ, Tomsk, Russia

[2] Sechenov First Moscow State Med Univ, Sechenov Moscow State Med Univ 1, Moscow, Russia

[3] Lomonosov Moscow State Univ, Moscow, Russia

[4] Inst Immunol, Natl Res Ctr, Moscow, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2024年 / 96卷 / 01期

关键词：

polymorphism; dipeptidyl peptidase-4 inhibitors; type 2 diabetes mellitus; GLP1R; DPP-4; KCNQ1; GLYCEMIC RESPONSE; EPIDEMIOLOGY; GENE;

D O I：

10.26442/00403660.2024.01.202553

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase -4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP -4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase -4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.

引用

页码：63 / 67

页数：5

共 50 条

[41] Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Wani, Javaid H.
Jennifer, John-Kalarickal
Fonseca, Vivian A.
CARDIOLOGY CLINICS, 2008, 26 (04) : 639 - +
[42] Potential Anti-Atherosclerotic Effects of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus
Sandeep Dhindsa
Ishwarlal Jialal
Current Diabetes Reports, 2014, 14
[43] Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus
Barnett, Anthony H.
Charbonnel, Bernard
Moses, Robert G.
Kalra, Sanjay
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (10) : 1919 - 1931
[44] Effect of Dipeptidyl Peptidase-4 Inhibitors on Adenosine Deaminase Activity in Type-2 Diabetes Mellitus
Jhajharia, Sumit
Pradhan, Tapaswini
Ekka, Anjana
Das, Ashok Kumar
BIOMEDICAL RESEARCH-INDIA, 2014, 25 (04): : 489 - 493
[45] Linagliptin: The Newest Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
Aletti, Rachael
Cheng-Lai, Angela
CARDIOLOGY IN REVIEW, 2012, 20 (01) : 45 - 51
[46] Potential Anti-Atherosclerotic Effects of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus
Dhindsa, Sandeep
Jialal, Ishwarlal
CURRENT DIABETES REPORTS, 2014, 14 (02)
[47] Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors
Cornell, Susan
JOURNAL OF DIABETES & METABOLISM, 2014, 5 (08)
[48] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
Jarvis, Courtney I.
Cabrera, Adriana
Charron, Derek
ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
[49] Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia
Tanner, Michael
ANNALS OF INTERNAL MEDICINE, 2016, 165 (04) : JC20 - JC20
[50] Incretin mimetics and dipeptidyl peptidase-4 inhibitors: Innovative treatment therapies for type 2 diabetes
Davidson, Jaime A.
Parente, Erika B.
Gross, Jorge L.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2008, 52 (06) : 1039 - 1049

← 1 2 3 4 5 →